Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 9 |
List of Tables | 9 | 1 |
List of Figures | 10 | 1 |
Introduction | 11 | 1 |
Global Markets Direct Report Coverage | 11 | 1 |
Malignant Pleural Mesothelioma Overview | 12 | 1 |
Therapeutics Development | 13 | 2 |
Pipeline Products for Malignant Pleural Mesothelioma Overview | 13 | 1 |
Pipeline Products for Malignant Pleural Mesothelioma Comparative Analysis | 14 | 1 |
Malignant Pleural Mesothelioma Therapeutics under Development by Companies | 15 | 2 |
Malignant Pleural Mesothelioma Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
Malignant Pleural Mesothelioma Pipeline Products Glance | 18 | 3 |
Late Stage Products | 18 | 1 |
Clinical Stage Products | 19 | 1 |
Early Stage Products | 20 | 1 |
Malignant Pleural Mesothelioma Products under Development by Companies | 21 | 3 |
Malignant Pleural Mesothelioma Products under Investigation by Universities/Institutes | 24 | 1 |
Malignant Pleural Mesothelioma Companies Involved in Therapeutics Development | 25 | 35 |
Advantagene, Inc. | 25 | 1 |
Amphera BV | 26 | 1 |
AnGes MG, Inc. | 27 | 1 |
ArQule, Inc. | 28 | 1 |
Bayer AG | 29 | 1 |
Biogen Inc | 30 | 1 |
Bionomics Limited | 31 | 1 |
Biotecnol Limited | 32 | 1 |
Boehringer Ingelheim GmbH | 33 | 1 |
Boston Biomedical, Inc. | 34 | 1 |
Bristol-Myers Squibb Company | 35 | 1 |
CanBas Co., Ltd. | 36 | 1 |
Concordia International Corp | 37 | 1 |
Eli Lilly and Company | 38 | 1 |
EnGeneIC Ltd | 39 | 1 |
F. Hoffmann-La Roche Ltd. | 40 | 1 |
Genelux Corporation | 41 | 1 |
GlaxoSmithKline Plc | 42 | 1 |
Juno Therapeutics Inc. | 43 | 1 |
MedImmune LLC | 44 | 1 |
Merck &Co., Inc. | 45 | 1 |
Millennium Pharmaceuticals Inc | 46 | 1 |
MolMed S.p.A. | 47 | 1 |
Morphotek, Inc. | 48 | 1 |
Novartis AG | 49 | 1 |
Ono Pharmaceutical Co., Ltd. | 50 | 1 |
Oxford BioMedica Plc | 51 | 1 |
Pharma Mar, S.A. | 52 | 1 |
Polaris Pharmaceuticals, Inc. | 53 | 1 |
Sellas Inc | 54 | 1 |
Targovax ASA | 55 | 1 |
VasGene Therapeutics, Inc. | 56 | 1 |
Verastem, Inc. | 57 | 1 |
Virttu Biologics Limited | 58 | 1 |
Vyriad Inc | 59 | 1 |
Malignant Pleural Mesothelioma Therapeutics Assessment | 60 | 12 |
Assessment by Monotherapy Products | 60 | 1 |
Assessment by Combination Products | 61 | 1 |
Assessment by Target | 62 | 3 |
Assessment by Mechanism of Action | 65 | 3 |
Assessment by Route of Administration | 68 | 2 |
Assessment by Molecule Type | 70 | 2 |
Drug Profiles | 72 | 224 |
alisertib Drug Profile | 72 | 6 |
amatuximab Drug Profile | 78 | 2 |
anetumab ravtansine Drug Profile | 80 | 3 |
bevacizumab Drug Profile | 83 | 9 |
BG-00001 Drug Profile | 92 | 1 |
BMS-986148 Drug Profile | 93 | 1 |
BNC-105 Drug Profile | 94 | 5 |
CBP-501 Drug Profile | 99 | 2 |
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia Drug Profile | 101 | 1 |
Cellular Immunotherapy to Target Mesothelin for Oncology Drug Profile | 102 | 1 |
Cellular Immunotherapy to Target WT1 for Oncology Drug Profile | 103 | 1 |
CSG-MESO Drug Profile | 104 | 1 |
defactinib hydrochloride Drug Profile | 105 | 7 |
durvalumab Drug Profile | 112 | 11 |
durvalumab + tremelimumab Drug Profile | 123 | 4 |
galinpepimut-S Drug Profile | 127 | 3 |
ganetespib Drug Profile | 130 | 12 |
GEN-0101 Drug Profile | 142 | 2 |
Gene Therapy for Malignant Pleural Mesothelioma Drug Profile | 144 | 1 |
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma Drug Profile | 145 | 1 |
GLONC-1 Drug Profile | 146 | 4 |
GSK-2256098 Drug Profile | 150 | 2 |
HSV-1716 Drug Profile | 152 | 3 |
iCasp9M28z Drug Profile | 155 | 1 |
JTCR-016 Drug Profile | 156 | 2 |
LY-3023414 Drug Profile | 158 | 2 |
MesoCancerVac Drug Profile | 160 | 1 |
MesoCART Drug Profile | 161 | 1 |
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology Drug Profile | 162 | 2 |
MTG-201 Drug Profile | 164 | 2 |
napabucasin Drug Profile | 166 | 7 |
NGR-hTNF Drug Profile | 173 | 6 |
nintedanib Drug Profile | 179 | 9 |
nivolumab Drug Profile | 188 | 34 |
Oncolytic Virus for Malignant Pleural Mesothelioma Drug Profile | 222 | 1 |
Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma Drug Profile | 223 | 1 |
ONCOS-102 Drug Profile | 224 | 3 |
OXB-301 Drug Profile | 227 | 3 |
pegargiminase Drug Profile | 230 | 7 |
pembrolizumab Drug Profile | 237 | 33 |
porfimer sodium Drug Profile | 270 | 2 |
rAd-IFN Drug Profile | 272 | 2 |
S-588210 Drug Profile | 274 | 1 |
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer Drug Profile | 275 | 1 |
TargomiRs Drug Profile | 276 | 2 |
TB-535 Drug Profile | 278 | 1 |
tivantinib Drug Profile | 279 | 5 |
trabectedin Drug Profile | 284 | 7 |
Vas-01 Drug Profile | 291 | 2 |
VS-5584 Drug Profile | 293 | 3 |
Malignant Pleural Mesothelioma Dormant Projects | 296 | 1 |
Malignant Pleural Mesothelioma Discontinued Products | 297 | 1 |
Malignant Pleural Mesothelioma Product Development Milestones | 298 | 16 |
Featured News &Press Releases | 298 | 1 |
Oct 19, 2016: SELLAS Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy OfficeR | 298 | 1 |
Sep 19, 2016: SELLAS Life Sciences Receives FDA Fast Track Designation of Galinpepimut-S for the Treatment of Malignant Pleural Mesothelioma | 298 | 1 |
Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke s launches clinical trial for cancer patients | 299 | 1 |
Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke s launches clinical trial of cancer combination therapy | 300 | 1 |
Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting | 301 | 2 |
May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting | 303 | 1 |
May 19, 2016: Bayer to Showcase Anetumab Ravtansine at ASCO 2016 | 304 | 1 |
May 09, 2016: LUME-Meso trial enrolls first patient: Boehringer Ingelheim s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma | 305 | 1 |
May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016 | 306 | 1 |
May 04, 2016: SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig) | 307 | 2 |
Apr 05, 2016: SELLAS Life Sciences Group Receives a Favorable Opinion for European Orphan Drug Designations for WT1 Cancer Vaccine (galinpepimut-S) for the Treatment of Acute Myeloid Leukemia and for Malignant Pleural Mesothelioma | 309 | 1 |
Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) | 309 | 2 |
Feb 29, 2016: SELLAS Life Sciences Announces FDA Orphan Drug Designation for WT1 Cancer Vaccine in Patients with Malignant Pleural Mesothelioma | 311 | 1 |
Jan 26, 2016: ImmunoGen Earns Milestone with Bayer s Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration | 312 | 1 |
Nov 18, 2015: Morphotek Announces Initiation of Amatuximab Study in First-Line, Unresectable, Malignant Pleural Mesothelioma Patients | 312 | 2 |
Appendix | 314 | 2 |
Methodology | 314 | 1 |
Coverage | 314 | 1 |
Secondary Research | 314 | 1 |
Primary Research | 314 | 1 |
Expert Panel Validation | 314 | 1 |
Contact Us | 314 | 1 |
Disclaimer | 315 | 1 |